Skip to content

Benin stakeholders co-design implementation approach for the PDMC trial

Stakeholders from across Benin’s health system met in Abomey-Calavi on 28–29 August 2024 to co-design the implementation approach for the PDMC Saves Lives trial. The workshop was convened by the Clinical Research Institute of Benin, in collaboration with the National Malaria Control Programme, and brought together representatives from the Ministry of Health, hospitals, departmental health directorates, community health services, WHO, USAID and the research team.Participants reviewed findings from the project’s qualitative research and discussed how post-discharge malaria chemoprevention could be delivered safely, effectively and sustainably to children recovering from severe anaemia or severe malaria. Key discussions focused on the choice of medicine, distribution arrangements, treatment adherence, communication between hospitals and community health services, and the implications for future scale-up.

Following detailed group work and plenary discussion, participants reached consensus that dihydroartemisinin–piperaquine (DP) should be used in the implementation trial. The decision considered its clinical effectiveness and the duration of protection it offers. Stakeholders agreed that any future use at scale should be reviewed by the National Malaria Control Programme in light of the trial findings, the wider policy context and developments in other malaria chemoprevention strategies.

Participants also agreed on a community-based delivery approach. Under the proposed model, PDMC medicines will be stored at district health facilities and delivered to eligible children at home by community health workers, under the supervision of qualified community health personnel. This approach aims to reduce the risks associated with families storing multiple treatment courses at home while supporting safe administration and follow-up.

The workshop highlighted the importance of:

  • clear referral and communication pathways between hospitals, health centres and community health workers;
  • accurate information on eligible children, treatment dates and local community health contacts;
  • appropriate training and supervision for community-based delivery;
  • practical reminder and adherence-support mechanisms, including home visits and telephone or SMS reminders;
  • monitoring medicine supply, safety, adherence and the potential for future integration into national policy.

 

A 13-member Trial Steering Committee was established to support and monitor implementation, with representation from national health authorities, hospitals, regional health structures, technical partners and research institutions.

The workshop provided an important platform for national stakeholders to shape the trial collaboratively and ensure that the implementation model reflects Benin’s health-system context. Its recommendations will inform the next stage of the PDMC Saves Lives trial and strengthen the evidence needed for future policy and scale-up decisions